What causes cell death in Parkinson's disease?
Identifieur interne : 001996 ( Main/Corpus ); précédent : 001995; suivant : 001997What causes cell death in Parkinson's disease?
Auteurs : Amitabh Gupta ; Valina L. Dawson ; Ted M. DawsonSource :
- Annals of Neurology [ 0364-5134 ] ; 2008-12.
Abstract
Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic‐based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration. Ann Neurol 2008;64 (suppl):S3–S15
Url:
DOI: 10.1002/ana.21573
Links to Exploration step
ISTEX:48D8E7F0128E42858FDB877EE27C7757866B4EA5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">What causes cell death in Parkinson's disease?</title><author><name sortKey="Gupta, Amitabh" sort="Gupta, Amitabh" uniqKey="Gupta A" first="Amitabh" last="Gupta">Amitabh Gupta</name><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation></author><author><name sortKey="Dawson, Valina L" sort="Dawson, Valina L" uniqKey="Dawson V" first="Valina L." last="Dawson">Valina L. Dawson</name><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation></author><author><name sortKey="Dawson, Ted M" sort="Dawson, Ted M" uniqKey="Dawson T" first="Ted M." last="Dawson">Ted M. Dawson</name><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:48D8E7F0128E42858FDB877EE27C7757866B4EA5</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21573</idno><idno type="url">https://api.istex.fr/document/48D8E7F0128E42858FDB877EE27C7757866B4EA5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001996</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">What causes cell death in Parkinson's disease?</title><author><name sortKey="Gupta, Amitabh" sort="Gupta, Amitabh" uniqKey="Gupta A" first="Amitabh" last="Gupta">Amitabh Gupta</name><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation></author><author><name sortKey="Dawson, Valina L" sort="Dawson, Valina L" uniqKey="Dawson V" first="Valina L." last="Dawson">Valina L. Dawson</name><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation></author><author><name sortKey="Dawson, Ted M" sort="Dawson, Ted M" uniqKey="Dawson T" first="Ted M." last="Dawson">Ted M. Dawson</name><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S15">S15</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">48D8E7F0128E42858FDB877EE27C7757866B4EA5</idno><idno type="DOI">10.1002/ana.21573</idno><idno type="ArticleID">ANA21573</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic‐based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration. Ann Neurol 2008;64 (suppl):S3–S15</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Amitabh Gupta MD, PhD</name><affiliations><json:string>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</json:string></affiliations></json:item><json:item><name>Valina L. Dawson PhD</name><affiliations><json:string>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</json:string><json:string>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</json:string><json:string>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD</json:string><json:string>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</json:string></affiliations></json:item><json:item><name>Ted M. Dawson MD, PhD</name><affiliations><json:string>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</json:string><json:string>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</json:string><json:string>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</json:string></affiliations></json:item></author><articleId><json:string>ANA21573</json:string></articleId><language><json:string>eng</json:string></language><abstract>Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic‐based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration. Ann Neurol 2008;64 (suppl):S3–S15</abstract><qualityIndicators><score>6.092</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>606</abstractCharCount><pdfWordCount>9263</pdfWordCount><pdfCharCount>61316</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>91</abstractWordCount></qualityIndicators><title>What causes cell death in Parkinson's disease?</title><genre><json:string>article</json:string></genre><host><volume>64</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>13</total><last>S15</last><first>S3</first></pages><issn><json:string>0364-5134</json:string></issn><issue>S2</issue><subject><json:item><value>Basic Issues</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/ana.21573</json:string></doi><id>48D8E7F0128E42858FDB877EE27C7757866B4EA5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/48D8E7F0128E42858FDB877EE27C7757866B4EA5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/48D8E7F0128E42858FDB877EE27C7757866B4EA5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/48D8E7F0128E42858FDB877EE27C7757866B4EA5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">What causes cell death in Parkinson's disease?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><notesStmt><note type="content">*Potential conflicts of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). A.G. has received honorarium from BI. V.L.D. has no relationship with BI. T.M.D. is a paid contributor. T.M.D. has consulted for BI in the past, but reports no consulting agreements with pharmaceutical companies at the time of publication of this manuscript.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">What causes cell death in Parkinson's disease?</title><author><persName><forename type="first">Amitabh</forename><surname>Gupta</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation></author><author><persName><forename type="first">Valina L.</forename><surname>Dawson</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation></author><author><persName><forename type="first">Ted M.</forename><surname>Dawson</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Institute for Cell Engineering, Department of Neurology and Neuroscience, Johns Hopkins University School of Medicine, 733 North Broadway, Suite 731, Baltimore, MD 21205</p></note><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12"></date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S15">S15</biblScope></imprint></monogr><idno type="istex">48D8E7F0128E42858FDB877EE27C7757866B4EA5</idno><idno type="DOI">10.1002/ana.21573</idno><idno type="ArticleID">ANA21573</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic‐based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration. Ann Neurol 2008;64 (suppl):S3–S15</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Basic Issues</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-03-03">Received</change><change when="2008-10-03">Registration</change><change when="2008-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/48D8E7F0128E42858FDB877EE27C7757866B4EA5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="250"><doi origin="wiley" registered="yes">10.1002/ana.v64:2+</doi><titleGroup><title type="supplementTitle">Unresolved Issues in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="64">64</numbering><numbering type="journalIssue">S2</numbering><numbering type="supplement" number="2">2</numbering></numberingGroup><coverDate startDate="2008-12">December 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.21573</doi><idGroup><id type="unit" value="ANA21573"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Basic Issues</title><title type="tocHeading1">Basic Issues</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="2008-03-03"></event><event type="manuscriptRevised" date="2008-09-30"></event><event type="manuscriptAccepted" date="2008-10-03"></event><event type="firstOnline" date="2009-01-06"></event><event type="publishedOnlineFinalForm" date="2009-01-06"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:FullText result:FullText" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">S3</numbering><numbering type="pageLast">S15</numbering></numberingGroup><correspondenceTo>Institute for Cell Engineering, Department of Neurology and Neuroscience, Johns Hopkins University School of Medicine, 733 North Broadway, Suite 731, Baltimore, MD 21205</correspondenceTo><objectNameGroup><objectName elementName="figure">Illustration</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA21573.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="121"></count><count type="wordTotal" number="10245"></count></countGroup><titleGroup><title type="main" xml:lang="en">What causes cell death in Parkinson's disease?<link href="#fn1"></link></title><title type="short" xml:lang="en">What Causes Cell Death in PD?</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Amitabh</givenNames><familyName>Gupta</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4"><personName><givenNames>Valina L.</givenNames><familyName>Dawson</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2 #af4" corresponding="yes"><personName><givenNames>Ted M.</givenNames><familyName>Dawson</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>tdawson@jhmi.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</unparsedAffiliation></affiliation></affiliationGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic‐based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration. Ann Neurol 2008;64 (suppl):S3–S15</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflicts of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). A.G. has received honorarium from BI. V.L.D. has no relationship with BI. T.M.D. is a paid contributor. T.M.D. has consulted for BI in the past, but reports no consulting agreements with pharmaceutical companies at the time of publication of this manuscript.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>What causes cell death in Parkinson's disease?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>What Causes Cell Death in PD?</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>What causes cell death in Parkinson's disease?</title></titleInfo><name type="personal"><namePart type="given">Amitabh</namePart><namePart type="family">Gupta</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Valina L.</namePart><namePart type="family">Dawson</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ted M.</namePart><namePart type="family">Dawson</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD</affiliation><description>Correspondence: Institute for Cell Engineering, Department of Neurology and Neuroscience, Johns Hopkins University School of Medicine, 733 North Broadway, Suite 731, Baltimore, MD 21205</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-12</dateIssued><dateCaptured encoding="w3cdtf">2008-03-03</dateCaptured><dateValid encoding="w3cdtf">2008-10-03</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">121</extent><extent unit="words">10245</extent></physicalDescription><abstract lang="en">Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic‐based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration. Ann Neurol 2008;64 (suppl):S3–S15</abstract><note type="content">*Potential conflicts of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). A.G. has received honorarium from BI. V.L.D. has no relationship with BI. T.M.D. is a paid contributor. T.M.D. has consulted for BI in the past, but reports no consulting agreements with pharmaceutical companies at the time of publication of this manuscript.</note><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.</note><subject><genre>article category</genre><topic>Basic Issues</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>2</number></detail><extent unit="pages"><start>S3</start><end>S15</end><total>13</total></extent></part></relatedItem><identifier type="istex">48D8E7F0128E42858FDB877EE27C7757866B4EA5</identifier><identifier type="DOI">10.1002/ana.21573</identifier><identifier type="ArticleID">ANA21573</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001996 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001996 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:48D8E7F0128E42858FDB877EE27C7757866B4EA5
|texte= What causes cell death in Parkinson's disease?
}}
| This area was generated with Dilib version V0.6.23. |  |